Ashurst advises on Boan Biotechs spinoff from Luye Pharma Group

Boan Biotech is an integrated biopharmaceutical company committed to developing, manufacturing and commercializing high-quality biologics in China and overseas. It focuses on the key therapeutic areas, including oncology, metabolism, autoimmunity, and ophthalmology. With years of experience, Boan Biotech has established its unique competitive advantages with a robust and risk-balanced product portfolio, an integrated biopharmaceutical platform covering "R&D-production-commercialization," and commercialization capabilities that continue to mature.

Ashurst represented Luye Pharma on its Hong Kong IPO in 2014, which was the largest pharmaceutical IPO globally in over three years and the winner of "Hong Kong equity issue – IFR Asia Review of the Year".

Lead partner Li Jiang commented: "We are very pleased to have acted on the successful Hong Kong IPO of Boan Biotech. The successful listing has once again demonstrated our strong capability in the healthcare and pharmaceutical industry. The transaction was completed on a very tight timetable and it was a testament to our collaborative effort across teams."

The transaction was led by partner Li Jiang, with the support from partners Frank Bi, Stuart Rubin, and teams from Hong Kong, London, Shanghai, New York, Frankfurt, Singapore and Paris.